The 2020 Biopharma Cold Chain Sourcebook is an invaluable resource. Based on detailed analysis of rapidly changing regulatory practices around the world and the growth of clinical and commercial shipping volumes worldwide.
Are you an industry supply chain/logistics manager who needs to organize and streamline your shipping processes for temperature-controlled samples and products, in the US and around the world? Are you a business development executive in the life sciences services industry looking to improve your company’s position in offering temperature-controlled technology and services to biopharma? For both of you—and many others—the 2020 Biopharma Cold Chain Sourcebook will be an invaluable resource. Based on detailed analysis of rapidly changing regulatory practices around the world, and the growth of clinical and commercial shipping volumes worldwide, the temperature-controlled delivery market is one of the most dynamic fields in life sciences today. Click on “Introduction” below to get our overview of the 2020 edition of the Sourcebook, and click on “Table of Contents” to review the chapter-by-chapter details of this 205-page report.
Sourcebook IntroSourcebook Table of Contents
Order now: The 2020 Biopharma Cold Chain Sourcebook can be delivered as hardcopy or a PDF. Call (917) 648-3919, or e-mail [email protected] for more details.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.